NASDAQ
16.09.26 | 21:59
1,180 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | TELA Bio COO/CFO Roberto Cuca steps down | 3 | Seeking Alpha | ||
| 31.08. | TELA Bio cuts 20% of workforce to reduce costs by $17M annually | 3 | Investing.com | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 31.08. | TELA Bio, Inc.: TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative | 277 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 31.08. | TELA Bio, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Tela Bio outlines 9- to 12-month sales ramp while withdrawing full-year revenue guidance | 1 | Seeking Alpha | ||
| 10.08. | TELA Bio GAAP EPS of -$0.20 misses by $0.03, revenue of $19.3M misses by $0.71M | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.08. | TELA Bio names Heather Getz as CEO and Director | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio Names Heather Getz CEO | 2 | RTTNews | ||
| 04.08. | TELA Bio appoints Heather Getz as chief executive officer | 1 | Investing.com | ||
| 04.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | TELA Bio, Inc.: TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director | 185 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 20.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 11.06. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tela Bio verfehlt Q1-Prognosen: Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 12.05. | TELA Bio Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 12.05. | TELA Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $19.1M beats by $0.1M | 1 | Seeking Alpha |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 126,88 | +1,86 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,220 | -4,12 % | Sarepta Therapeutics climbs 10%, rebounding from recent slide | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,180 | +1,24 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| MYRIAD GENETICS | 3,280 | -2,58 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,999 | -2,94 % | Phio Pharmaceuticals Corp.: Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma | Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,525 | -2,23 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 77,62 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 49,120 | -7,95 % | Enliven Therapeutics auf Morgan Stanley Konferenz: Liquidität, Studien und die CML-Marktchance | ||
| INHIBRX BIOSCIENCES | 101,77 | -3,64 % | Inhibrx, Eikon rise after insider buying | ||
| ARCUTIS BIOTHERAPEUTICS | 26,150 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,305 | -3,32 % | Dyne Therapeutics auf Morgan Stanley Konferenz: Pläne zur Markteinführung im Fokus | ||
| QIAGEN | 37,195 | +0,04 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 42,210 | +0,09 % | Harmony Biosciences stellt auf Cantor-Konferenz erweiterte Wachstumsstrategie vor | ||
| SUMMIT THERAPEUTICS | 17,310 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| VERA THERAPEUTICS | 31,800 | -6,61 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,180 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.